Identification and characterization of human ARIP2 and its relation to breast cancer

Cytokine

Volumn 46, Issue 2, 2009, Pages 251-259

  Li, Zhan Dong ^a   Wu, Yin ^a   Bao, Yong Li ^a   Yu, Chun Lei ^a   Guan, Li Li ^a   Wang, Yue Zeng ^a,b   Meng, Xiang Ying ^a   Li, Yu Xin ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Activin; Activin receptor II (ActRII); Breast cancer; Human activin receptor interacting protein 2 (hARIP2)

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR INTERACTING PROTEIN 2; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST FIBROADENOMA; BREAST HYPERPLASIA; CELL PROLIFERATION; CELL STRAIN MCF 7; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EMBRYO; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MUCINOUS CARCINOMA; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BREAST; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES;

MURINAE;

EID: 65049084765     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.02.009     Document Type: Article

References (29)

1. Tsuchida K. Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 4 2 (2004) 157
2. Bao Y.L., Tsuchida K., Liu B., et al. Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1/ERK2 MAPK signaling pathways. J Endocrinol 184 3 (2005) 493
3. Liu B, Bao YL, Wei Z, et al. Isolation and characterization of proteins interacting with activin type II receptors Chem Res Chinese U 2006;22(2):217-220.
4. Chen Y.G., Wang Q., Lin S.L., et al. Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis. Exp Biol Med 231 (2006) 534-544
5. Wrana J.L. Regulation of Smad activity. Cell 100 2 (2000) 189-192
6. Panopoulou E., Gillooly D.J., Wrana J.L., et al. Early endosomal regulation of Smad-dependent signaling in endothelial cells. J Biol Chem 277 20 (2002) 18046
7. Shoji H., Nakamura T., Van den Eijnden-van Raaij A.J., et al. Identification of a novel type II activin receptor, type IIA-N, induced during the neural differentiation of murine P19 embryonal carcinoma cells. Biochem Biophys Res Commun 246 (1998) 320-324
8. Ethier J.F., Lussier J.G., and Silversides D.W. Bovine activin receptor type IIB messenger ribonucleic acid displays alternative splicing involving a sequence homologous to Src-homology 3 domain binding sites. Endocrinology 138 (1997) 2425-2434
9. Shoji H., Tsuchida K., Kishi H., et al. Identification and characterization of a PDZ protein that interacts with activin type II receptors. J Biol Chem 275 No. 8 (2000) 5485-5492 [Issue of February 25]
10. Feuer E.J., Wun L.M., Boring C.C., et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst 85 (1993) 892-897
11. Sharkey F.E., Allred D.C., and Valente P.T. Breast. In: Dmjanov I., and Linder J. (Eds). Anderson's pathology. 3rd ed. (1996), Mosby, St. Louis 2354-2385
12. Uzzan B., Nicolas P., Cucherat M., et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64 (2004) 2941-2955
13. Konstantinovsky S., Nielsen S., Vyberg M., et al. Angiogenic molecule expression is down regulated in effusion from breast cancer. Breast Cancer Res Treat 94 (2005) 71-80
14. Fiegl H., Millinger S., Goebel G., et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66 (2006) 29-33
15. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 57 (2007) 43-66
16. Liu Q.Y., Niranjan B., Gomes P., et al. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res 56 (1996) 1155-1163
17. Gorska A.E., Joseph H., Derynck R., et al. Dominantnegative interference of the transforming growth factor βtype II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ 9 (1998) 229-238
18. Derynck R., Akhurst R.J., and Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29 (2001) 117-129
19. Di Loreto C., Reis F.M., Cataldi P., et al. Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. Eur J Endocrinol 141 (1999) 190-194
20. Wakefield L.M., Piek E., and Bottinger E.P. TGF-β signaling in mammary gland development and tumorigenesis. J Mamm Gland Biol Neoplasia 6 (2001) 67-82
21. Xie W., Mertens J.C., Reiss D.J., et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 62 (2002) 497-505
22. Jeruss J.S., Santiago J.S., and Woodruff T.K. Localization of activin and inhibin subunits, receptors and Smads in the mouse mammary gland. Mol Cell Endocrinol 203 (2003) 185-196
23. Ying S.Y., and Zhang Z. Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line. Breast Cancer Res Treat 37 (1996) 151-160
24. Tsuchida K., Vaughan J.M., Wiater E., et al. Inactivation of activin-dependent transcription by kinase-deficient activin receptors. Endocrinology 136 (1995) 5493-5503
25. Jonk L.J., Itoh S., Heldin C.H., et al. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 273 33 (1998) 21145-21152
26. Ahsan H., Reagan-Shaw S., Breur J., et al. Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins. Cancer Lett 249 (2007) 198-208
27. Matsuzaki T., Hanai S., Kishi H., et al. Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway. J Biol Chem 277 No. 21 (2002) 19008-19018 [Issue of May 24]
28. Zimmers T.A., Davies M.V., Koniaris L.G., et al. Induction of cachexia in mice by systemically administered myostatin. Science 296 (2002) 1486-1488
29. Wankell M., Munz B., Hübner G., et al. Impaired wound healing in transgenic mice overexpressing the activin antagonist follistatin in the epidermis. EMBO J 20 (2001) 5361-5372